Brain scans reveal how a Weight-Loss drug may rewire food cravings

NCT ID NCT07732426

Recruiting now Knowledge-focused Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study investigates whether semaglutide, a GLP-1 drug used for weight loss, alters dopamine activity in the brain when people with obesity and food addiction see, smell, and taste food. Thirty adults will receive semaglutide for 8 weeks and undergo PET brain scans to measure dopamine receptor binding while viewing food images and drinking chocolate milk. The goal is to understand how the drug affects the brain's reward system and food-related behaviors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (Wegovy) injections over 8 weeks
What this could lead to: If it works, this could reveal how GLP-1 drugs like semaglutide affect food cravings and reward pathways in the brain, pointing toward better treatments for food addiction.
What could go wrong: This is a small, early-stage study with only 30 participants and no control group, so results may not apply broadly. The brain scan technique is indirect and may not capture real-world eating behavior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOOD ADDICTION TENDENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOOD ADDICTION TENDENCY OBESITY OVERWEIGHT

Contacts and locations

Locations

Seoul National University Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.